Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Strategy Sales & Earnings Generic Drugs

Perrigo Wary Of ‘Destroying’ Value Through Premature Sale

As Covid-19 ProAir Impact Revealed In First Quarter

  • Analysis

Executive Summary

Perrigo has been looking to separate its Prescription US generics business for almost two years but has ruled out an immediate or rushed transaction in existing market conditions. Meanwhile, management took the time to assess the financial rewards and ramifications of Perrigo’s recently-launched generic ProAir product, with demand “substantially higher than anticipated” in the wake of COVID-19.

Table

View full table

Related Content

Generics Bulletin
Generics Bulletin
HBW Insight
Generics Bulletin
Generics Bulletin
Generics Bulletin
Generics Bulletin

Topics

Related Companies

Tags:
Strategy Sales & Earnings Generic Drugs
Latest Headlines

Who’s Hired? Teva Brings New Legal Head Onboard

Bolar Exemption India Files: Roche Blocks Alleged Infringer Of Evrysdi Patent

Celltrion Secures Deal With PBM Express Scripts For Subcutaneous Infliximab

Podcast: The Global Generics & Biosimilars Awards 2024

See All
UsernamePublicRestriction

Register

GB149861

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By